	Durable and Additive Disease Control at 52 Weeks With Ixekizumab Plus Tirzepatide Versus Ixekizumab Alone in Adults With Psoriatic Arthritis and Obesity or Overweight: Additional Results From a Randomized Clinical Trial. Arthritis Rheumatol Merola JF, Kartman CE, Fischer P, Mease P, Kivitz A, Sattar N, Coates LC, Aletaha D, Sun L, Chen Y, Marulkar K, Bello N, Cardoso A, Genovese MC, Ogdie A. PMID: 43012507 [PubMed - as supplied by publisher]
	Evaluation of Anti-psoriatic Treatment Awareness, Prescription Patterns, and Adverse Effects in Patients with Psoriasis - A Questionnaire-Based Study. Indian J Dermatol Pillay S, Tripathi RK, Jalgaonkar SV, Gole P, Mahajan S. PMID: 43011999 [PubMed]
	Optimizing rheumatology referral in patients with psoriasis: a community-based pilot study of four screening questionnaires within a collaborative dermatology-rheumatology pathway. Clin Rheumatol Arendse G, Al Horoub Y, Walker K, Gardner K, Odeshi O, Awan S, Arendse R. PMID: 43009641 [PubMed - as supplied by publisher]
	Multidomain efficacy and safety of IL-17A and IL-17A/F inhibitors versus adalimumab in biologic-naÃ¯ve psoriatic arthritis: A systematic review and Meta-analysis of comparative trials. Autoimmun Rev Ball DL, Duong N, Hackett GD 3rd, Scott GH, Coates LC, Sparks JA. PMID: 43008998 [PubMed - as supplied by publisher]
	Two-Year Treatment Persistence and Effectiveness of Ixekizumab in Psoriatic Arthritis in Italian Clinical Practice: Results from the ROUTE-IXE Study. Rheumatol Ther Luchetti Gentiloni MM, Foti R, Selmi C, Cipollone F, Iannone F, Dagna L, Idolazzi L, Chimenti MS, Gentileschi S, Ramonda R, Ciccia F, Zabotti A, Lubrano E, Caporali R, D'Agostino MA, Scarlini A, Ippati S, Giurdanella F, Avitabile A. PMID: 43007639 [PubMed - as supplied by publisher]
	Regulatory T cell dysfunction and therapeutic advances in rheumatoid arthritis, psoriasis, vitiligo, and systemic lupus erythematosus. Front Immunol Liang Y, Feng H, Wang Y, Li J, Niu X. PMID: 43005606 [PubMed - indexed for MEDLINE]
	Linking skin to system: LL-37 as a potential molecular link between psoriasis and its comorbidities. Autoimmun Rev Deng G, Luo Y, Wu W, Ru Y, Song J, Zhang Z, Ma X, Kuai L, Li B, Zhang Y, Ding X. PMID: 43003168 [PubMed - as supplied by publisher]
	IL23-axis cytokines and C-reactive protein as dissociable biomarkers of vascular recovery in psoriasis: A hypothesis. Immunol Res Zhou Y. PMID: 43002317 [PubMed - indexed for MEDLINE]
	Effectiveness of Combination Therapy (Topical and Phototherapy) Versus Monotherapy (Phototherapy Alone) in the Treatment of Moderate to Severe Plaque Psoriasis: A Systematic Review and Meta-Analysis. Cureus Alamri A, Alzhrani G, Sindi M, Alharbi A, Alsamadani A, Alraddadi R, Aldraibi S, Fathi AB, Aljedani HA, Aljahdali D, Alharbi A. PMID: 43001168 [PubMed]
	Dynamic permanent magnetic field alleviates psoriasis-like skin lesions in mice by modulating the il-23/il-17 axis: an enhanced combined approach with calcipotriol. Lasers Med Sci Lai D, Tian Y, He S, Wang W, He Y, Wang H, Liu S, Cheng S. PMID: 43000523 [PubMed - indexed for MEDLINE]
	Switching to Tildrakizumab 200 mg after Anti-IL-17 Failure in Moderate-to-Severe Psoriasis: A 52-Week Prospective Real-World Study. Dermatol Ther (Heidelb) Di Brizzi EV, Carlo P, Nicoletti MM, Franzese P, Caccavale S, Argenziano G, Balato A. PMID: 42999962 [PubMed - as supplied by publisher]
	Systemic psoriasis biomarkers differentially impact clinical responses to deucravacitinib and apremilast in moderate-to-severe plaque psoriasis: Insight from phase 3 studies. J Invest Dermatol Luo Y, Bal AB, Schafer P, Krueger JG. PMID: 42998753 [PubMed - as supplied by publisher]
	Mitochondria as immunometabolic hubs in psoriasis: pathogenic mechanisms and therapeutic prospects. Front Immunol Zhao F, Guo Y, Tong X, Zhou X, Jiao Y, Han R, Chen H, Qi R. PMID: 42997206 [PubMed - indexed for MEDLINE]
	The effect of personal mastery on depression and anxiety in patients with psoriasis: The mediating role of social support and acceptance of illness. Medicine (Baltimore) Yang YC, Li SJ, Zhang XG, Guo SB, Xue LL, Wei F, Ma XX, Bai YZ. PMID: 42994877 [PubMed - indexed for MEDLINE]
	Risk of cancer in psoriasis patients treated with biologic therapy: A BADBIR cohort study. J Eur Acad Dermatol Venereol Alabas OA, Mason KJ, Lunt M, Ryan S, Reynolds NJ, Smith CH, Bunker CB, Griffiths CEM, Green AC, Warren RB. PMID: 42992706 [PubMed - as supplied by publisher]
	Local treatments of psoriasis and atopic dermatitis: From pharmacological targets to meta-analyses. Therapie Ouakrat R, Marcombes C, Sbidian E, Le Cleach L. PMID: 42988660 [PubMed - as supplied by publisher]
	Response to Han et al., 'Infection risk among psoriasis biologic-new users: a cohort study on the French National Health Data System'. J Am Acad Dermatol Trong Khoi Le T, Vo TT, Sbidian E. PMID: 42988123 [PubMed - as supplied by publisher]
	Comment on "Infection risk among psoriasis biologic-new users: A cohort study on the French National Health Data System". J Am Acad Dermatol Han Y, Zhao C, Jiang W, Li S. PMID: 42988121 [PubMed - as supplied by publisher]
	Foot and ankle involvement is common across the spondyloarthritis spectrum with distinct anatomical and clinical patterns: a post hoc cross-sectional analysis of the ASAS-PerSpA study. Rheumatol Int Gezer HH, Duruöz MT, Aktas I, Akar S, Sahin N, Akgul O, Hizmetli S, Melikoglu MA, Kalyoncu U, Capkin E, Nazl, Yilmaz F, Sezer I, Ataman S. PMID: 42986442 [PubMed - indexed for MEDLINE]
	Case Report: Dupilumab-associated psoriasiform eruption followed by depigmentation in a patient with prurigo nodularis and Vogt-Koyanagi-Harada disease. Front Immunol Otsuka M, Sato E, Katayama S, Imafuku S. PMID: 42984631 [PubMed - indexed for MEDLINE]

Articles 1 - 20 / 28768

Page 1 of 1439



		Time frame

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Privacy Policy